Outlook Therapeutics Completes Enrollment For NORSE EIGHT Clinical Trial Evaluating ONS-5010 For Wet AMD, With Topline Results Expected In Q4 2024 And BLA Resubmission Planned For Q1 2025
Portfolio Pulse from Benzinga Newsdesk
Outlook Therapeutics has completed enrollment for its NORSE EIGHT clinical trial, which evaluates ONS-5010 for wet AMD. Topline results are expected in Q4 2024, with a BLA resubmission planned for Q1 2025.
September 04, 2024 | 12:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Outlook Therapeutics has completed enrollment for its NORSE EIGHT trial evaluating ONS-5010 for wet AMD. Results are expected in Q4 2024, with a BLA resubmission in Q1 2025, which could impact future stock performance.
The completion of enrollment in the NORSE EIGHT trial is a significant milestone for Outlook Therapeutics. The expected results in Q4 2024 and the planned BLA resubmission in Q1 2025 are key future events that could positively impact the stock if the results are favorable. This news is highly relevant to OTLK as it directly pertains to their product development and regulatory strategy.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100